The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of health care professional interventions on completion of therapy in patients receiving high-dose interferon-alfa 2b adjuvant therapy for high-risk melanoma.
Teresa M. Petrella
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Richard Tozer
Research Funding - Merck Canada
Gregory John Knight
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Jose Chang
Honoraria - Merck
Research Funding - Merck
Bryn Lloyd Pressnail
Research Funding - Merck
Sudhashree Rajagopal
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Nancy Gregorio
Research Funding - Merck
Other Remuneration - Merck
Caroline M. Hamm
Research Funding - Merck
Tina Cheng
Research Funding - Merck
Michael Smylie
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Andre Galarneau
Employment or Leadership Position - Merck Canada
Jean-François Pouliot
Employment or Leadership Position - Merck Canada
Stock Ownership - Merck